FDA approves Unicycive’s Oxylanthanum Carbonate (OLC)?
$3,380 Vol.
Rules
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Unicycive Therapeutics’ new drug application (NDA) for Oxylanthanum Carbonate (OLC) as a treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) by June 28, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Created At: Jun 17, 2025, 7:13 PM UTC
Volume
$3,380End Date
Jun 28, 2025Created At
Jun 17, 2025, 7:13 PM UTCResolver
0x6A9D22261...Outcome proposed: No
No dispute
Final outcome: No
$3,380 Vol.
FDA approves Unicycive’s Oxylanthanum Carbonate (OLC)?
About
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Unicycive Therapeutics’ new drug application (NDA) for Oxylanthanum Carbonate (OLC) as a treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) by June 28, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Volume
$3,380End Date
Jun 28, 2025Created At
Jun 17, 2025, 7:13 PM UTCResolver
0x6A9D22261...Outcome proposed: No
No dispute
Final outcome: No
Beware of external links.
Beware of external links.
Beware of external links.
Beware of external links.